Outcomes of Primary Percutaneous Coronary Intervention in Post COVID-19 Patients presenting with ST Segment Elevation Myocardial Infarction | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 5, Volume 92, Issue 1, July 2023, Page 5478-5486 PDF (804.62 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2023.305787 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hany Mohamed Fakhry  ; Nadeem M. Elmasry; Ali A. El-Abd; Haitham G. Helmy
| ||||
| Abstract | ||||
| Background: COVID-19 can cause a wide range of thrombotic diseases, including acute coronary syndromes (ACS). While these thrombotic diseases occur during acute infection, evidence on the long-term thrombotic consequences of COVID-19 remain unknown. Objective: The aim of the current study was to establish the particular coronary angiographic findings, as well as the procedural and clinical effectiveness of revascularization in post COVID-19 patients presenting with STEMI. Patients and methods: A total100 patients presented to Ain Shams University Hospitals with ST Segment Elevation Myocardial Infarction (STEMI) managed by primary percutaneous coronary intervention (PCI). Participants were divided into two groups: Group (A) included 50 patients who developed COVID-19 infection in the previous 6 months, and Group (B) included 50 patients who deny COVID-19 infection in the previous 6 months. Group (A) was divided into two subgroups: the Early Post-COVID subgroup, which included 16 patients who developed STEMI within 8 weeks of infection, and the Late Post-COVID subgroup, which included 34 patients who developed STEMI >8-24 weeks after infection. Results: The Early Post-COVID subgroup had a statistically significant high thrombus load on angiography, with 81.3% versus 48% in the control group. This resulted in a statistically significant increase in the utilization of pre-dilatation (56.2% versus 24%) and thrombus aspiration (43.8% versus 4%) in the Early Post- COVID grouping (P-values 0.015 and 0.001, respectively). Coronary no-reflow was a substantially more common in the Early post-COVID subgroup (62.5%) than in the control group (22%). This translated into a higher Major Adverse Cardiovascular Events (MACE) among Early Post-COVID patients, at 31.3% versus 6% in the control group. Conclusion: The thrombogenic impact of COVID-19 on STEMI outcomes continues even after infection clearance being greatest during the first 8 weeks following infection and thereafter diminishes. It has an impact on the angiographic, procedural, and overall clinical success of in-hospital revascularization. | ||||
| Keywords | ||||
| COVID-19; STEMI; Primary PCI; Thrombosis | ||||
|
Statistics Article View: 122 PDF Download: 199 |
||||
